Efficacy and Safety of Catheter Ablation for Atrial Arrhythmias in Solid Organ Transplant Recipients: A Single‐Center Experience
Clinical Cardiology · 2026-05 · 49 (5)
DOI: 10.1002/clc.70345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, online erschienen am 20.05.2026. Verfasst von Piotr Gardziejczyk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Electrophysiology, Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Catheter Ablation, Atrial Fibrillation, Organ Transplantation, Transplant Recipients. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Atrial arrhythmias are common among solid organ transplant recipients and independently associated with increased morbidity, mortality, and impaired graft survival. Pharmacological management is substantially limited by interactions with immunosuppressive therapy. Despite growing clinical need, data on the feasibility, safety, and efficacy of catheter ablation in this population remain scarce.
Methods
Single‐center, retrospective, matched cohort study. All consecutive solid organ transplant recipients who underwent catheter ablation of symptomatic left atrial arrhythmias between July 2021 and June 2024 were included. Each was matched 1:2 to non‐transplant controls by age, sex, BMI, arrhythmia type, and ablation modality. All procedures were performed using contemporary techniques: pulsed field ablation (PFA) or very high‐power short‐duration (vHPSD) radiofrequency ablation.
Results
Sixty‐six patients were included: 22 transplant recipients and 44 matched controls. Arrhythmia‐free survival at 12 months after a 2‐month blanking period was 68.2% versus 76.2% ( p = 0.49; HR 1.57, 95% CI 0.60–4.12). Periprocedural complications occurred in 9.1% versus 4.6% ( p = 0.60); no cases of stroke, cardiac tamponade, or access site complications requiring surgical intervention were recorded in either group. In the kidney transplant subgroup ( n = 17), eGFR remained stable at 12 months (41.8 ± 12.1 vs. 43.8 ± 15.3 mL/min/1.73 m², p = 0.34), with no clinically significant decline in renal function observed.
Conclusion
Catheter ablation for complex atrial arrhythmias in solid organ transplant recipients was feasible using contemporary ablation techniques, without major procedural complications, and no excess safety or efficacy signal was observed at 12 months relative to matched controls. Prospective multicentre studies are needed to confirm these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Electrophysiology, Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland.
ORCID-Profile: Piotr Gardziejczyk, Ewa Wlazłowska-Struzik, Jakub Baran
Zitieren
APA
Gardziejczyk, P., Skrzyńska-Kowalczyk, M., Skowrońska, M., Wlazłowska-Struzik, E., Szymkiewicz, P., Pruszczyk, P., & Baran, J. (2026). Efficacy and Safety of Catheter Ablation for Atrial Arrhythmias in Solid Organ Transplant Recipients: A Single‐Center Experience. Clinical Cardiology, 49(5). https://doi.org/10.1002/clc.70345
Vancouver
Gardziejczyk P, Skrzyńska-Kowalczyk M, Skowrońska M, Wlazłowska-Struzik E, Szymkiewicz P, Pruszczyk P, et al. Efficacy and Safety of Catheter Ablation for Atrial Arrhythmias in Solid Organ Transplant Recipients: A Single‐Center Experience. Clinical Cardiology. 2026;49(5). doi:10.1002/clc.70345
BibTeX
@article{Gardziejczyk2026,
author = {Gardziejczyk, Piotr and Skrzyńska-Kowalczyk, Martyna and Skowrońska, Marta and Wlazłowska-Struzik, Ewa and Szymkiewicz, Pawel and Pruszczyk, Piotr and Baran, Jakub},
title = {Efficacy and Safety of Catheter Ablation for Atrial Arrhythmias in Solid Organ Transplant Recipients: A Single‐Center Experience},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {5},
doi = {10.1002/clc.70345}
}
EUVIMED